Hiroshi Hagino1, Yukari Uemura2, Satoshi Mori3, Teruki Sone4, Hiroaki Ohta5, Toshitaka Nakamura6. 1. School of Health Science, Faculty of Medicine, Tottori University, Tottori, Japan. hagino@tottori-u.ac.jp. 2. Biostatistics Section, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan. 3. Bone and Joint Surgery, Seirei Hamamatu General Hospital, Shizuoka, Japan. 4. Department of Nuclear Medicine, Kawasaki Medical School, Okayama, Japan. 5. International Medical Center, Fujita Health University, Aichi, Japan. 6. Japan Osteoporosis Foundation, Tokyo, Japan.
Abstract
INTRODUCTION: To identify predictors for incident fractures in patients on pharmaceutical treatment for osteoporosis by a secondary analysis of the Japanese Osteoporosis Intervention Trial protocol number 4 (JOINT-04), which was a 2-year, randomized, parallel-group, controlled trial of minodronate and raloxifene in women with primary osteoporosis. MATERIALS AND METHODS: This was a prospective, observational study using JOINT-04 data, in which biomarkers, such as undercarboxylated osteocalcin (ucOC), N-telopeptide of type 1 collagen, tartrate-resistant acid phosphatase 5b (TRACP-5b), bone alkaline phosphatase, homocysteine, and pentosidine in blood, and physical functions, such as the timed up and go test and one-leg standing test with eyes open (OLST), and the fall risk index, were measured. The relationships of incident morphometric vertebral fractures during the treatment period, as well as prevalent vertebral fractures, and baseline data were analyzed. RESULTS: The full analysis set of the JOINT-04 included 3247 patients (1623 in the minodronate group and 1624 in the raloxifene group). The hazard ratio (95% confidence interval) for incident vertebral fractures over 2 years of pharmacotherapy, adjusted for confounders, was 0.93 (0.90-0.96) for ucOC, 1.15 (1.08-1.23) for TRACP-5b, 1.02 (1.01-1.03) for pentosidine, 0.91 (0.88-0.94) for the OLST, and 1.27 (1.01-1.60) for the fall risk index, which were all independent predictors. CONCLUSION: Evaluating fracture risk for patients with osteoporosis considering these potential risk factors for fracture in addition to the established risk factors may be useful when starting pharmaceutical treatment.
RCT Entities:
INTRODUCTION: To identify predictors for incident fractures in patients on pharmaceutical treatment for osteoporosis by a secondary analysis of the Japanese Osteoporosis Intervention Trial protocol number 4 (JOINT-04), which was a 2-year, randomized, parallel-group, controlled trial of minodronate and raloxifene in women with primary osteoporosis. MATERIALS AND METHODS: This was a prospective, observational study using JOINT-04 data, in which biomarkers, such as undercarboxylated osteocalcin (ucOC), N-telopeptide of type 1 collagen, tartrate-resistant acid phosphatase 5b (TRACP-5b), bone alkaline phosphatase, homocysteine, and pentosidine in blood, and physical functions, such as the timed up and go test and one-leg standing test with eyes open (OLST), and the fall risk index, were measured. The relationships of incident morphometric vertebral fractures during the treatment period, as well as prevalent vertebral fractures, and baseline data were analyzed. RESULTS: The full analysis set of the JOINT-04 included 3247 patients (1623 in the minodronate group and 1624 in the raloxifene group). The hazard ratio (95% confidence interval) for incident vertebral fractures over 2 years of pharmacotherapy, adjusted for confounders, was 0.93 (0.90-0.96) for ucOC, 1.15 (1.08-1.23) for TRACP-5b, 1.02 (1.01-1.03) for pentosidine, 0.91 (0.88-0.94) for the OLST, and 1.27 (1.01-1.60) for the fall risk index, which were all independent predictors. CONCLUSION: Evaluating fracture risk for patients with osteoporosis considering these potential risk factors for fracture in addition to the established risk factors may be useful when starting pharmaceutical treatment.
Entities:
Keywords:
Fall risk; One-leg standing test; Pentosidine; TRACP-5b; Timed up and go test
Authors: D Massera; S Xu; M D Walker; R J Valderrábano; K J Mukamal; J H Ix; D S Siscovick; R P Tracy; J A Robbins; M L Biggs; X Xue; J R Kizer Journal: Osteoporos Int Date: 2019-06-21 Impact factor: 4.507
Authors: Peggy M Cawthon; Terri L Blackwell; Lynn M Marshall; Howard A Fink; Deborah M Kado; Kristine E Ensrud; Jane A Cauley; Dennis Black; Eric S Orwoll; Steven R Cummings; John T Schousboe Journal: J Bone Miner Res Date: 2014-09 Impact factor: 6.741
Authors: Su-Min Jeong; Dong Wook Shin; Kyungdo Han; Jin Hyung Jung; Sohyun Chun; Hee-Won Jung; Ki Young Son Journal: Bone Date: 2019-07-16 Impact factor: 4.398
Authors: Daniel Schoene; Sandy M-S Wu; A Stefanie Mikolaizak; Jasmine C Menant; Stuart T Smith; Kim Delbaere; Stephen R Lord Journal: J Am Geriatr Soc Date: 2013-01-25 Impact factor: 5.562
Authors: S Fujiwara; T Nakamura; H Orimo; T Hosoi; I Gorai; A Oden; H Johansson; J A Kanis Journal: Osteoporos Int Date: 2008-02-22 Impact factor: 4.507
Authors: B A M Larsson; L Johansson; H Johansson; K F Axelsson; N Harvey; L Vandenput; P Magnusson; E McCloskey; E Liu; J A Kanis; D Sundh; M Lorentzon Journal: Osteoporos Int Date: 2020-10-21 Impact factor: 4.507